

Why particle density matters. Beyond mean tumor dose.

Even distribution of SIR-Spheres Y-90 resin microspheres within the tumor creates overlapping radiation clouds




Mean dose doesn't tell you the whole story[1]



High particle density leads to optimal coverage with homogeneous dose distribution

Low particle density leads to cold areas and heterogeneous dose distribution - "Swiss-cheese effect"



Beta energy travels up to an average of 2.5 mm, highlighting the importance of tumor coverage[2,3]

Y-90 deposits most of its energy in tissue within the first few millimeters.

Range of beta energy in tissue:

- Maximum: 11 mm
- Average: 2.5 mm

Order Deadline *(16:00 CET preceding week to delivery W-1)*	Delivery Day	Delivered Activity*	Calibration Day
Wednesday W-1	*Monday*	6.0	Wednesday
	Tuesday	4.6	Wednesday
	Wednesday	3.6	Wednesday
Friday W-1	*Wednesday*	10.0	Sunday
		4.6	Thursday
	Thursday	7.8	Sunday
		3.6	Thursday
	Friday	6.0	Sunday

*Activities at 7AM GMT of a shipping vial received up to 4 days pre-calibration. Calibration at 23:00 GMT: 3 GBq +/- 10%

Intended Purpose: SIR-Spheres® Y-90 resin microspheres are intended for Brachytherapy and are permanently implanted via the hepatic artery to deliver therapy to hepatic tumors. **Indications For Use:** SIR-Spheres® Y-90 resin microspheres are indicated for the treatment of: unresectable hepatocellular carcinoma (HCC), or unresectable metastatic liver tumors from primary colorectal cancer (mCRC) in patients refractory to or intolerant of chemotherapy, or unresectable intrahepatic cholangiocarcinoma (iCCA), or hepatic metastases by neuroendocrine tumours (mNET), or other liver metastases. **Consult www.sirtex.com/eu/products/sir-spheres/sir-spheres-y-90-resin-microspheres/about-sir-spheres/contraindications-and-potential-adverse-events/ for a complete listing of indications, contraindications, warnings, precautions, adverse events and risks.** *July 2026*


References: 1. Maxwell AWP et al. Cardiovasc Intervent Radiol 2022; 45: 958–969. **2.** Tandon P. Medical Physics 2006; 33: 2744–2750. **3.** Kim SP et al. Phys Med 2019: 68: 132-145.

Manufacturer
Sirtex Medical Inc. 300 Unicorn Park Drive, 2nd Fl. Woburn, MA 01801 USA Tel: +1 888 474 7839
Europe, Middle East & Africa Sirtex Medical Europe GmbH Joseph-Schumpeter-Allee 33 53227 Bonn Germany Tel: +49 228 1840 730
www.sirtex.com @SirtexMedical company/sirtex-medical-limited
SIR-Spheres® is a registered trademark of Sirtex SIR-Spheres Pty Ltd. ©2026 Sirtex Medical Europe GmbH APM-EMEA-002-01-25 V2

SIRTeX | SIR-Spheres® Y-90 resin microspheres

FLEXdose Delivery Programme

What you need. When you need it.



*Activities at 7AM GMT of a shipping vial received up to 4 days pre-calibration. Calibration at 23:00 GMT: 3 GBq +/- 10%

FLEXdose Delivery Programme
The Activity You Want. The Coverage You Need.

For a personalized treatment:

- Delivery options every day of the week
- Five activities ranging from 3.6 to 10 GBq* available
- Patient-tailored activity and particle density

Adapt specific activity and particle density to the treatment scenario

Targeted liver volume
subsegmental, segmental, lobar

Tumor vascularization
relatively hypovascular, hypervascular, impaired arteries from previous treatments

Treatment goal
enable surgery, palliative


Did you know?

The vial can be shipped up to 4 days before calibration and remains usable for up to 6 days afterward, offering treatment flexibility. Prepare the patient's personalized dose from the vial whenever needed.



The flexibility to personalize your treatment: Balancing the appropriate activity with the right coverage





Activity on average 44.5 million microspheres in each delivery vial*	10.0 GBq	7.8 GBq	6.0 GBq	4.6 GBq	3.6 GBq
Activity/ Microsphere	225 Bq	175 Bq	135 Bq	103 Bq	81 Bq
Dose Draw Example: 1.2 GBq					
# Microspheres (million)	~5.3	~6.8	~8.9	~11.6	~14.8
Suggestions for use:**	• Radiation segmentectomy	• Multiple segmental, selective injections • Small hypovascular tumors	• Poor vascular capacity • Radiation bi-segmentectomy	• Radiation lobectomy • Large/Centrally located tumors	• Excessive tumor (widespread coverage) • Lobar treatments with palliative intent

*Standard deviation of 2.6 million. Engineering test results on file. Activities for the morning of the delivery day at 07:00 GMT.
** Expert opinion Prof Irene Bargellini (Diagnostic and Interventional Radiology, University of Turin, Italy)